Previous 10 | Next 10 |
Axonics, Inc. (AXNX) Q1 2021 Earnings Conference Call May 06, 2021 4:30 PM ET Company Participants Neil Bhalodkar – Investor Relations Raymond Cohen – Chief Executive Officer Dan Dearen – President and Chief Financial Officer Conference Call Participants Bob Hopkins ...
Axonics Modulation Technologies (AXNX): Q1 GAAP EPS of -$0.57 misses by $0.17.Revenue of $34.4M (+30.8% Y/Y) beats by $6.47M.Axonics anticipates fiscal year 2021 net revenue to be in the range of $176 million to $180 million vs. consensus of $169.90M, which would represent growth of approxima...
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial results for the first quarter ended March 31, 2021. “This quarter’s reve...
Top-rated stocks in our research that also have a strong track record of beating analyst expectations. Stock ideas cutting across most sectors. Over 50 ideas worth considering for watch lists. For further details see: Stocks With The Best History Of Beating Estimates
Axonics Inc. (NASDAQ:AXNX) traded today at a new 52-week high of $63.50. So far today approximately 153,000 shares have been exchanged, as compared to an average 30-day volume of 487,000 shares. Based on a current price of $63.20, Axonics Inc. is currently 7.3% above its average consensu...
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that has developed and is commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to participate in the BofA Securities 2021 Virtual Healthcare Conference on Thursday, May 13, 2021....
Axonics Inc. (NASDAQ:AXNX) traded at a new 52-week high today of $61.61. So far today approximately 153,000 shares have been exchanged, as compared to an average 30-day volume of 483,000 shares. Axonics Inc is a United stated based medical technology company. It focuses on the design, de...
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that has developed and is commercializing novel products for the treatment of bladder and bowel dysfunction, will report first quarter 2021 financial results after the market closes on Thursday, May 6, 2021. In conjun...
Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a global medical technology company that has developed and is commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to participate in the virtual Barclays Global Healthcare Conference on Marc...
Endotronix Appoints Industry Veteran Dan Dearen to Board of Directors Expands company's financial expertise during time of growth in advance of commercial launch PR Newswire LISLE, Ill. , March 2, 2021 /PRNewswire/ -- Endotronix, Inc., a digital health and me...
News, Short Squeeze, Breakout and More Instantly...
Axonics Modulation Technologies Inc. Company Name:
AXNX Stock Symbol:
NASDAQ Market:
Axonics Modulation Technologies Inc. Website:
Axonics, Inc. (NASDAQ: AXNX) has caught the attention of the investment community today with its bullish price action. The company's shares have moved 0.09% on the day to $68.5. Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulat...
Generated record revenue, gross margin and net income in 2Q24 Axonics, Inc. (Nasdaq: AXNX), a medical technology company that develops, manufactures and commercializes innovative and minimally invasive products to treat bladder and bowel dysfunction, today reported financial results f...
Viridien ADR (CGGYD) is expected to report for Q2 2024 Civitas Resources Inc. (CIVI) is expected to report $2.9 for Q2 2024 Aptiv PLC (APTV) is expected to report $1.37 for Q2 2024 Ardelyx Inc. (ARDX) is expected to report $-0.1 for Q2 2024 Beazer Homes USA Inc. (BZH) is expected ...